Association of RSV-related hospitalization and non-compliance with Palivizumab among commercially insured infants: a retrospective claims analysis
Open Access
- 19 July 2013
- journal article
- research article
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 13 (1) , 334
Abstract
Palivizumab has been shown to decrease the incidence of hospitalization due to respiratory syncytial virus (RSV) in infants at risk of severe RSV disease. We examined the association between compliance with palivizumab dosing throughout the RSV season and risk of RSV-related hospitalization in clinical practice. Subjects who were born and discharged from the hospital before the RSV season and received ≥1 palivizumab dose during their first RSV season were identified from a large US commercial health insurance database between 01/01/03 and 12/31/09. Subjects were deemed compliant if they received ≥5 palivizumab doses without gaps (>35 days) and their first dose was received by November 30. RSV-related hospitalizations were identified using ICD-9-CM diagnosis codes and examined over 2 observation periods: post-index dose and RSV season. A Cox proportional hazard model was used to evaluate the association between non-compliance and RSV-related hospitalization. Of the 5,003 subjects who received palivizumab, 62% were deemed non-compliant. Non-compliant subjects had significantly higher unadjusted rates of RSV-related hospitalizations compared to compliant subjects during both observation periods (post-index: 6.1 vs. 2.8 per 100 infant seasons, p < 0.001; RSV season: 5.9% vs. 2.3%; p < 0.001). In multivariate analyses, non-compliance was significantly associated with higher risk of RSV-related hospitalization (HR = 2.01; p < 0.001). Of the 225 RSV-related hospitalizations observed during the RSV season, 61 (27%) occurred before the first dose of palivizumab. Subjects who did not receive monthly dosing of palivizumab throughout the RSV season had significantly higher rates of RSV-related hospitalizations. The RSV-related hospitalizations prior to the first dose of palivizumab suggest some dosing was started too late.Keywords
This publication has 26 references indexed in Scilit:
- Population Pharmacokinetics of Palivizumab, a Humanized Anti-Respiratory Syncytial Virus Monoclonal Antibody, in Adults and ChildrenAntimicrobial Agents and Chemotherapy, 2012
- Respiratory Syncytial Virus-associated Hospitalizations Among Infants and Young Children in the United States, 1997–2006The Pediatric Infectious Disease Journal, 2012
- Respiratory outcomes, utilization and costs 12 months following a respiratory syncytial virus diagnosis among commercially insured late-preterm infantsCurrent Medical Research and Opinion, 2010
- Respiratory syncytial virus testing during bronchiolitis episodes of care in an integrated health care delivery system: A retrospective cohort studyClinical Therapeutics, 2010
- Healthcare costs within a year of respiratory syncytial virus among medicaid infantsPediatric Pulmonology, 2010
- Compliance with RSV prophylaxis: Global physicians’ perspectivesPatient Preference and Adherence, 2009
- Evaluation of Compliance With Palivizumab Recommendations in a Multicenter Study of Young Children Presenting to the Emergency Department With BronchiolitisPediatric Emergency Care, 2007
- Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart diseaseThe Journal of Pediatrics, 2003
- Factors Predicting Compliance with Palivizumab in High-Risk InfantsAmerican Journal of Perinatology, 2001
- Palivizumab, a Humanized Respiratory Syncytial Virus Monoclonal Antibody, Reduces Hospitalization From Respiratory Syncytial Virus Infection in High-risk InfantsPediatrics, 1998